Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newer antifungal agents.

Walid Abuhammour1, Eyassu Habte-Gaber

  • 1Department of Pediatrics, Hurley Medical Center, Michigan State University-College of Human Medicine, Flint, Michigan 48503-5993, USA. wabuham1@hurleymc.com

Indian Journal of Pediatrics
|April 15, 2004
PubMed
Summary

Invasive fungal infections are a major threat, especially in vulnerable populations. Newer antifungal drugs like lipid-based amphotericin B, voriconazole, and caspofungin offer improved treatment options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Encephalopathy With Guillain-Barré Syndrome Secondary to Extensively Multidrug-Resistant Salmonella Typhi Infection: A Case Report.

Cureus·2026
Same author

Risk factors of diagnosis of and mortality from late onset neonatal sepsis caused by multidrug-resistant organisms - a case-control study at a tertiary Hospital in the UAE.

Annals of medicine·2025
Same author

Procalcitonin in Pediatric Emergency Medicine.

Advances in pediatrics·2025
Same author

From multisystem inflammatory syndrome in children to secondary hemophagocytic lymphohistiocytosis a series of misfortunate events: case report and review of literature.

Sudanese journal of paediatrics·2024
Same author

IFIH1 loss of function predisposes to inflammatory and SARS-CoV-2-related infectious diseases.

Scandinavian journal of immunology·2024
Same author

Chronic granulomatous disease in the United Arab Emirates: clinical and molecular characteristics in a single center.

Frontiers in immunology·2023

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) cause significant morbidity and mortality, particularly in premature infants, immunocompromised children, and patients on immunosuppressants.
  • Amphotericin B, discovered in 1955, has been a primary antifungal treatment.
  • Recent advancements have expanded antifungal options, including novel formulations and drug classes.

Purpose of the Study:

  • To review recent developments in antifungal therapies.
  • To discuss the clinical utility of lipid-based amphotericin B, voriconazole, and caspofungin.

Main Methods:

  • Literature review of antifungal drug development and clinical applications.
  • Discussion of pharmacological properties and therapeutic uses of key antifungal agents.

Main Results:

  • Development of less toxic lipid-based amphotericin B formulations.
  • Introduction of voriconazole, an advanced triazole antifungal.
  • Advent of echinocandin lipopeptides, exemplified by caspofungin.

Conclusions:

  • The antifungal armamentarium has significantly expanded in the last decade.
  • Lipid-based amphotericin B, voriconazole, and caspofungin represent important therapeutic advancements for IFIs.
  • These newer agents offer improved safety and efficacy profiles for managing invasive fungal infections.

Related Experiment Videos